On Sept. 18, 2017, Medigen Vaccine Biologics (MVC) amended an existing agreement with the National Institutes of Health (NIH) to expand dengue vaccine market territories from 17 countries to 26 countries in order to include Brunei, Cambodia, Laos, Myanmar, Papua New Guinea, and high dengue incidence areas like Sri Lanka, Bangladesh, Nepal and Bhutan.

Following the amendment, MVC began to develop, manufacture, sell, and sublicense dengue vaccines in most Southeast Asia, South Asia, and Middle East countries, covering 1/3 of global population of approximately 2.47 billion people. According to WHO, dengue is prevalent in almost all tropical areas including South East Asia, South Asia, Central and South America.